12,309 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Purchased by Fox Run Management L.L.C.

Fox Run Management L.L.C. purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 12,309 shares of the company’s stock, valued at approximately $69,000.

A number of other hedge funds also recently modified their holdings of FDMT. KLP Kapitalforvaltning AS bought a new stake in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $48,000. PNC Financial Services Group Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after acquiring an additional 3,630 shares during the last quarter. Daiwa Securities Group Inc. boosted its position in 4D Molecular Therapeutics by 5,291.8% in the fourth quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock valued at $55,000 after buying an additional 9,737 shares in the last quarter. AlphaQuest LLC boosted its holdings in shares of 4D Molecular Therapeutics by 3,665.2% during the 4th quarter. AlphaQuest LLC now owns 14,835 shares of the company’s stock valued at $83,000 after acquiring an additional 14,441 shares in the last quarter. Finally, AXQ Capital LP bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth about $110,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. Royal Bank of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research note on Monday, March 3rd. Leerink Partners decreased their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a report on Monday, January 13th. Chardan Capital dropped their price objective on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Tuesday, March 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of 4D Molecular Therapeutics in a research note on Saturday, March 22nd. Finally, BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the company from $40.00 to $15.00 in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $30.63.

4D Molecular Therapeutics Trading Up 2.0 %

Shares of FDMT stock opened at $3.63 on Friday. The firm has a fifty day simple moving average of $4.58 and a two-hundred day simple moving average of $7.09. 4D Molecular Therapeutics, Inc. has a 12 month low of $3.45 and a 12 month high of $31.87. The firm has a market capitalization of $168.08 million, a PE ratio of -1.27 and a beta of 2.83.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Friday, February 28th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.10). On average, equities analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.